Anti-VEGF therapy is not a magic bullet for diabetic retinopathy

[1]  Y. Sun,et al.  [The rational use of anti-vascular endothelial growth factor drugs to assist the treatment of diabetic retinopathy]. , 2019, [Zhonghua yan ke za zhi] Chinese journal of ophthalmology.

[2]  Jennifer K. Sun,et al.  Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial. , 2019, JAMA.

[3]  D. Roth,et al.  Ranibizumab Induces Regression of Diabetic Retinopathy in Most Patients at High Risk of Progression to Proliferative Diabetic Retinopathy. , 2018, Ophthalmology. Retina.

[4]  Jennifer K. Sun,et al.  Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial , 2018, JAMA ophthalmology.

[5]  S. Sivaprasad,et al.  Mechanistic Evaluation of Panretinal Photocoagulation Versus Aflibercept in Proliferative Diabetic Retinopathy: CLARITY Substudy , 2018, Investigative ophthalmology & visual science.

[6]  A Lotery,et al.  Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial , 2017, The Lancet.

[7]  N. Bressler,et al.  Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. , 2016, Ophthalmology.

[8]  Jennifer K. Sun,et al.  Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. , 2015, JAMA.

[9]  中华医学会眼科学会眼底病学组.  我国糖尿病视网膜病变临床诊疗指南(2014年) , 2014 .